Ann: General Meeting Presentation, page-12

There were a few of points in the presentation I found interesting.

Slide 5: The COVID-19 diagnostics venture has been placed within the Lyramid business division, which is an obvious fit.

Slide 8: Expansion of the product range and market geographies is planned. I wonder what the source might be of the intended rapid PCR tests. Which geographies?



Slide 6: The proportioning of annual revenues is informative. With Slide 7 indicating Consumer Health to remain unchanged from FY2019, the implication is that a 50+% Biotech revenue increase is anticipated for FY2020.

Slide 19: An upcoming milestone is Antibody test sales and commercial partnerships. I wonder what type of partnership(s) is envisaged.

With a managerial appointment as well the Company clearly has a confident view on the viability of the new diagnostics push.

Did anyone registered for the Meeting pick up any points of note?